Phosphorylcholine epitope (PC epitope (or ChoP epitope))

Phosphorylcholine epitopes refer to molecular surface features containing phosphorylcholine exposed on a wide range of prokaryotic (e.g., *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Pseudomonas aeruginosa*, *Neisseria* spp.) and eukaryotic cells or their membrane components[1][5][6][7]. These epitopes are commonly present on cell wall-associated teichoic acids, lipopolysaccharides, or membrane phospholipids, and are recognized as immunogenic determinants by the host immune system. In bacteria, phase-variable expression of phosphorylcholine modulates immune evasion by limiting antibody binding and complement-mediated killing[1]. In humans, phosphorylcholine is a component of membrane phospholipids (notably phosphatidylcholine, sphingomyelin) and acts as an epitope on apoptotic cells and oxidized lipoproteins. Its exposure can function as a danger signal, promoting inflammation or, conversely, modulating immune responses through natural antibodies[2][4][8]. Therapeutically, monoclonal antibodies against phosphorylcholine are under investigation for their potential to dampen inflammatory responses in conditions such as myocardial ischemia-reperfusion injury and atherosclerosis[2]. The roles and mechanisms of these epitopes are highly context-dependent, with both protective and pathogenic outcomes in different disease states[2][4][1].

Other names

phosphocholine epitopeChoP epitopePC epitopecholine phosphate epitope

Antibodies targeting phosphorylcholine can bind these epitopes, neutralize proinflammatory activity, reduce recruitment of inflammatory immune cells, and attenuate tissue remodeling post-injury. Proposed anti-infective effects through immune recognition and clearance of bacteria expressing PC epitopes.